JSR Forms Life Sciences Unit and Acquires MBL’s US Operations
JSR became a majority shareholder of Japan’s MBL last fall. The latest purchase involves MBL’s US operations. MBL will be fully integrated into JSR Life Sciences. Tim Lowery, senior vice president of Emerging Technologies at JSR Micro, the parent unit of JSR Life Sciences, was named CEO of MBL. A manufacturer of fine chemicals and petrochemical products, JSR’s chromatography investments include partnerships with BIA Separations and Natrix Separations.
Sunnyvale, CA 4/18/16; Sunnyvale, CA 4/21/16—Publicly held Japanese materials and polymer firm JSR has established a new business unit, JSR Life Sciences, which includes its large-scale purification and chromatography, exosome, magnetic and latex bead, biopolymer, surface chemistry and microfluidic products for life science and diagnostic markets. Eric R. Johnson was named head of the unit. “We know that we need to engage experts and markets outside of Japan, and we see the US and Europe as key regions for the growth of our life science businesses,” stated JSR President and Representative Director Mitsunobu Koshiba. The same week, JSR Life Sciences announced the acquisition of a majority stake in the US subsidiary of its Medical & Biological Laboratories (MBL) business. MBL US develops research products and technologies for immunology, cell biology and protein analysis, as well as assays for the analysis of disease biomarkers. JSR Micro stated that the acquisition will expand its diagnostic and research products portfolio.
